Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes are found in about one-third of cancers.
• Aberrant neuroblastoma-RAS (NRAS) signaling drives tumor progression in approximately 20% of melanoma patients, with limited therapeutic options.
• Targeting downstream pathways of mutant NRAS is a promising therapeutic strategy for NRAS-driven malignancies.

Purpose of the Study:

• To investigate the role of Polo-like kinase 1 (Plk1) in NRAS-mutant melanoma.
• To evaluate the efficacy of combining mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and Plk1 inhibitors in NRAS-mutant melanoma.
• To elucidate the mechanisms underlying the synergistic effects of MEK and Plk1 inhibition.

Main Methods:

• In vitro and in vivo studies using NRAS-mutant melanoma models.
• Pharmacologic inhibition of Plk1 and MEK pathways.
• Assessment of tumor xenograft size, cell growth, cell cycle arrest, and apoptosis.
• Analysis of the p53 signaling pathway.

Main Results:

• Mutant NRAS induces Plk1 expression, and Plk1 inhibition stabilizes NRAS-mutant melanoma xenografts.
• The combination of MEK and Plk1 inhibitors significantly reduces NRAS-mutant melanoma cell growth in vitro and causes xenograft regression in vivo.
• Synergistic effects are mediated by independent cell cycle arrest and increased apoptosis, with a key role for the p53 signaling pathway.

Conclusions:

• A combination of MEK and Plk1 inhibitors represents a promising therapeutic strategy for NRAS-driven melanoma.
• This combination therapy induces cell cycle arrest and apoptosis, offering a potential new treatment modality for NRAS-mutant tumors.
• The findings suggest that targeting MEK and Plk1 concurrently could be effective for NRAS-mutant melanomas and potentially other NRAS-driven cancers.